Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADES-1: KITE-363 or KITE-753 in Relapsed/Refractory B-cell Lymphoma
NCT04989803Phase 2Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Oct 2021
- Primary completion
- Feb 2030
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 6
01
Overview
A Phase 2 trial of KITE-363, KITE-753 in B cell lymphoma, sponsored by Kite Pharma. Started Oct 2021; status: active, not recruiting.
02
Drugs
KITE-363KITE-753
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04989803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989803.